TF-EVs may be used as biomarker for VTE in glioblastoma, as both TF-EV levels and activity have been associated with increased VTE incidence.73, 91A randomized controlled trial with advanced cancer patients reported a VTE risk reduction of 80% in patients with high TF-EV levels using thromboprophylaxis compared to high TF-EV patients without prophylactic treatment,133thus demonstrating the value of TF-EVs as prognostic biomarker for VTE. This evidence concerns the gene TF and cancer.